Clinical Study
AGR2 Predicts Tamoxifen Resistance in Postmenopausal Breast Cancer Patients
Table 1
Characteristics of patients.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Annotations. Switch of the tamoxifen to an aromatase inhibitor was carried out due to tamoxifen's side effects (mostly endometrial hyperplasia). All seven patients achieved partial remission in the course of tamoxifen therapy. Patients who achieved complete or partial (reduction of disease by 30% or more) remission or had long-lasting disease stabilization (stable disease for at least 33 months; median of PFS). Patients who never responded to primary treatment or achieved stable disease for less than 12 months during the period of primary treatment. |